ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

EDIT vs CCCC // OPERATING MARGIN

Editas Medicine Inc. (NASDAQ) VS. C4 Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EDIT 1 — CCCC 2
■ METRIC PARITY
operating-margins
-60.00%
operating-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EDIT VS. CCCC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC EDIT CCCC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -24.46% — TIE /fcf-yield <GO>
Operating Margin ACTIVE -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 25.40% 1.00% +24.40 EDIT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.1 56.6 -6.50 CCCC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $410.1M $414.6M -$4.5M CCCC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR EDIT REV CCCC REV EDIT GROSS % CCCC GROSS % EDIT FCF CCCC FCF
FY 2025 $40.5M $35.9M — — -$165.8M -$99.3M
FY 2024 $32.3M $35.6M — — -$219.1M -$65.3M
FY 2023 $78.1M $20.8M — — -$132.2M -$106.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EDIT // BETA —
CCCC // BETA —